200 related articles for article (PubMed ID: 18625773)
21. [Rate of genotypic mutations and resistance to antiretroviral drugs in a general hospital].
Fernández Lisón LC; Fernández Pereira LM; Romero Chala S
Farm Hosp; 2011; 35(4):191-6. PubMed ID: 21087876
[TBL] [Abstract][Full Text] [Related]
22. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes.
Poveda E; de Mendoza C; Parkin N; Choe S; García-Gasco P; Corral A; Soriano V
AIDS; 2008 Mar; 22(5):611-6. PubMed ID: 18317002
[TBL] [Abstract][Full Text] [Related]
23. Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
Marcelin AG; Flandre P; de Mendoza C; Roquebert B; Peytavin G; Valer L; Wirden M; Abbas S; Katlama C; Soriano V; Calvez V
Antivir Ther; 2007; 12(2):247-52. PubMed ID: 17503666
[TBL] [Abstract][Full Text] [Related]
24. Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.
Norelli S; El Daker S; D'Ostilio D; Mele F; Mancini F; Taglia F; Ruggieri A; Ciccozzi M; Cauda R; Ciervo A; Barreca ML; Pistello M; Bendinelli M; Savarino A
Curr HIV Res; 2008 Jun; 6(4):306-17. PubMed ID: 18691029
[TBL] [Abstract][Full Text] [Related]
25. Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
BMC Infect Dis; 2009 Sep; 9():154. PubMed ID: 19751502
[TBL] [Abstract][Full Text] [Related]
26. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.
Brindeiro PA; Brindeiro RM; Mortensen C; Hertogs K; De Vroey V; Rubini NP; Sion FS; De Sá CA; Machado DM; Succi RC; Tanuri A
J Clin Microbiol; 2002 Dec; 40(12):4512-9. PubMed ID: 12454144
[TBL] [Abstract][Full Text] [Related]
27. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
[TBL] [Abstract][Full Text] [Related]
28. External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.
Marcelin AG; Chazallon C; Gérard L; Saïdi Y; Aboulker JP; Girard PM; Calvez V; Piketty C
J Acquir Immune Defic Syndr; 2006 May; 42(1):127-8. PubMed ID: 16639354
[No Abstract] [Full Text] [Related]
29. Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
Int J STD AIDS; 2011 Nov; 22(11):617-20. PubMed ID: 22096044
[TBL] [Abstract][Full Text] [Related]
30. Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Mata-Munguía C; Escoto-Delgadillo M; Torres-Mendoza B; Flores-Soto M; Vázquez-Torres M; Gálvez-Gastelum F; Viniegra-Osorio A; Castillero-Manzano M; Vázquez-Valls E
BMC Bioinformatics; 2014 Mar; 15():72. PubMed ID: 24629078
[TBL] [Abstract][Full Text] [Related]
31. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
[TBL] [Abstract][Full Text] [Related]
32. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
[TBL] [Abstract][Full Text] [Related]
33. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.
Larder BA; Hertogs K; Bloor S; van den Eynde CH; DeCian W; Wang Y; Freimuth WW; Tarpley G
AIDS; 2000 Sep; 14(13):1943-8. PubMed ID: 10997398
[TBL] [Abstract][Full Text] [Related]
34. Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.
Teto G; Nka AD; Fokam J; Bouba Y; Takou D; Fabeni L; Carioti L; Armenia D; Semengue ENJ; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Ndjolo A
Sci Rep; 2022 Jan; 12(1):1374. PubMed ID: 35082353
[TBL] [Abstract][Full Text] [Related]
35. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
36. Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.
Bethell R; Scherer J; Witvrouw M; Paquet A; Coakley E; Hall D
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1019-24. PubMed ID: 22098079
[TBL] [Abstract][Full Text] [Related]
37. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
Yeni P
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S91-4. PubMed ID: 14562864
[TBL] [Abstract][Full Text] [Related]
38. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
Descamps D; Lambert-Niclot S; Marcelin AG; Peytavin G; Roquebert B; Katlama C; Yeni P; Felices M; Calvez V; Brun-Vézinet F
J Antimicrob Chemother; 2009 Mar; 63(3):585-92. PubMed ID: 19147519
[TBL] [Abstract][Full Text] [Related]
39. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
40. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Arribas JR
Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
